Physician profile
Ashok Jain
NPI 1780680470
$2,653.38
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $1,537 · 2021: $553 · 2023: $17.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $439.48 | 2020-2021 | |
| Eisai INC. | $348.04 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $326.66 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $311.42 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $180.26 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $156.14 | 2019-2021 | |
| Alkermes, INC. | $109.72 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $97.01 | 2019-2021 | |
| Noven Therapeutics, LLC | $96.37 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.26 | 2020-2021 | |
| Allergan, INC. | $69.42 | 2019-2020 | |
| Indivior INC. | $69.24 | 2019-2020 | |
| Neos Therapeutics, LP | $68.21 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $60.57 | 2020 | |
| Adlon Therapeutics L.P. | $36.21 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $24.73 | 2020-2021 | |
| Mdd US Operations, LLC | $22.08 | 2019 | |
| Shire North American Group INC | $21.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.22 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.47 | 2020 | |
| Abbott Laboratories | $17.93 | 2023 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $16.57 | 2019 | |
| Neuronetics, INC. | $14.74 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.85 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.49 | 2019 | |
| Merck Sharp & Dohme LLC | $11.98 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.